Bal Pharma share news and announcements
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Last close ₹81.09down ₹3.48 (4.11%)BSE ₹81.60
Share price at the NSE close on 23 Oct 2026. Previous close ₹84.57.
52-week range of traded prices to 23 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹129 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 17.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 Jul 2026
- 1.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.48%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 22 Jul 2026
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day.
- 18,242
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Bal Pharma quarterly results
Aug12Wed
The board met on 12 Aug 2026 to consider financial results and other business matters
Notice filed 5 Aug 2026
Bal Pharma annual reports, presentations and earnings calls
The company's own documents, latest first.Bal Pharma financials, year by year
Annual reports17
- Annual report, year to Mar 2026 (opens in a new tab)26 Aug 2026
- Annual report, year to Mar 2025 (opens in a new tab)2 Sep 2025
- Annual report, year to Mar 2024 (opens in a new tab)30 Aug 2024
- Annual report, year to Mar 2023 (opens in a new tab)30 Aug 2023, a zip file
- Annual report, year to Mar 2022 (opens in a new tab)5 Sep 2022, a zip file
12 earlier reports
- Annual report, year to Mar 2021 (opens in a new tab)1 Sep 2021, a zip file
- Annual report, year to Mar 2020 (opens in a new tab)4 Sep 2020, a zip file
- Annual report, year to Mar 2019 (opens in a new tab)27 Aug 2019, a zip file
- Annual report, year to Mar 2018 (opens in a new tab)24 Sep 2018, a zip file
- Annual report, year to Mar 2017 (opens in a new tab)25 Sep 2017, a zip file
- Annual report, year to Mar 2016 (opens in a new tab)24 Sep 2016, a zip file
- Annual report, year to Mar 2015 (opens in a new tab)24 Aug 2015, a zip file
- Annual report, year to Mar 2014 (opens in a new tab)22 Aug 2014, a zip file
- Annual report, year to Mar 2013 (opens in a new tab)21 Aug 2013, a zip file
- Annual report, year to Mar 2012 (opens in a new tab)18 Sep 2012, a zip file
- Annual report, year to Mar 2011 (opens in a new tab)16 Dec 2011, a zip file
- Annual report, year to Mar 2010 (opens in a new tab)17 Sep 2010, a zip file
Investor presentations2
Bal Pharma share news and announcements
550 announcements, routine notices left out, newest first. Page 1 of 11.
Oct 2026
Sep 2026
25 Sep · Management
10 Sep · Legal
The exchange asked on 10 Sep 2026
7 Sep · General Updates
Aug 2026
26 Aug · General Updates
13 Aug · General Updates
Jul 2026
Jun 2026
22 Jun · Legal
Exchange has sought clarification from Bal Pharma Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.
May 2026
12 May · Management
Apr 2026
Feb 2026
Jan 2026
8 Jan · Meeting
Nov 2025
12 Nov · Board meeting
7 Nov · General Updates
Sep 2025
30 Sep · Management
Aug 2025
12 Aug · Corporate action
Jul 2025
Jun 2025
30 Jun · Meeting
May 2025
5 May · Management
Apr 2025
18 Apr · General Updates
Mar 2025
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts).
- 13 Aug 2026Resultsdown 2.50%−2.4 pts vs Nifty 500market median −0.7% · five sessions −6.3% (−5.1 pts vs Nifty 500) · volume 0.6× usual · delivery −5.7 pts against usual · The announcement (opens in a new tab)
- 29 May 2026Resultsdown 6.54%−5.2 pts vs Nifty 500market median −0.7% · five sessions −9.7% (−7.6 pts vs Nifty 500) · volume 1.7× usual · delivery −3.0 pts against usual · The announcement (opens in a new tab)
- 12 May 2026Board or managers changeddown 6.05%−3.9 pts vs Nifty 500market median 0.0% · five sessions −11.1% (−9.7 pts vs Nifty 500) · volume 2.3× usual · delivery −16.6 pts against usual · The announcement (opens in a new tab)
- 12 Feb 2026Resultsup 4.67%+5.2 pts vs Nifty 500market median −0.7% · five sessions +10.1% (+10.6 pts vs Nifty 500) · volume 2.6× usual · delivery −11.0 pts against usual · The announcement (opens in a new tab)
- 13 Nov 2025Resultsdown 2.07%−2.0 pts vs Nifty 500market median −0.7% · five sessions −4.4% (−4.7 pts vs Nifty 500) · volume 1.8× usual · delivery +6.9 pts against usual · The announcement (opens in a new tab)
- 12 Aug 2025Resultsdown 2.15%−1.9 pts vs Nifty 500market median −0.7% · five sessions −3.7% (−5.6 pts vs Nifty 500) · volume 1.3× usual · delivery +3.5 pts against usual · The announcement (opens in a new tab)
- 30 May 2025Dividenddown 2.50%−2.2 pts vs Nifty 500market median 0.0% · five sessions −0.4% (−0.7 pts vs Nifty 500) · volume 2.2× usual · delivery −3.5 pts against usual · The announcement (opens in a new tab)
- 19 May 2025Board or managers changedup 2.64%+2.7 pts vs Nifty 500market median 0.0% · five sessions −0.3% (+0.1 pts vs Nifty 500) · volume 1.8× usual · delivery +12.7 pts against usual · The announcement (opens in a new tab)
- 30 May 2024Dividendup 0.75%+1.8 pts vs Nifty 500market median 0.0% · five sessions −10.5% (−9.6 pts vs Nifty 500) · volume 21.8× usual · delivery −30.9 pts against usual · The announcement (opens in a new tab)
- 29 May 2024Dividendup 19.98%+20.6 pts vs Nifty 500market median 0.0% · five sessions +4.5% (+9.5 pts vs Nifty 500) · volume 25.0× usual · delivery −12.1 pts against usual · The announcement (opens in a new tab)
20 earlier announcements
- 25 Sep 2023Dividendup 2.14%+2.1 pts vs Nifty 500market median 0.0% · five sessions +2.2% (+2.1 pts vs Nifty 500) · volume 0.8× usual · delivery +4.0 pts against usual · The announcement (opens in a new tab)
- 24 Aug 2023Board or managers changeddown 0.32%−0.2 pts vs Nifty 500market median 0.0% · five sessions +2.2% (+2.1 pts vs Nifty 500) · volume 0.1× usual · delivery +12.0 pts against usual · The announcement (opens in a new tab)
- 30 May 2023Dividenddown 0.42%−0.6 pts vs Nifty 500market median 0.0% · five sessions +7.1% (+6.5 pts vs Nifty 500) · volume 0.5× usual · delivery +1.7 pts against usual · The announcement (opens in a new tab)
- 16 May 2023Board or managers changedup 1.33%+1.7 pts vs Nifty 500market median 0.0% · five sessions +2.5% (+2.8 pts vs Nifty 500) · volume 0.1× usual · delivery +9.2 pts against usual · The announcement (opens in a new tab)
- 25 Apr 2023Credit ratingdown 3.79%−4.0 pts vs Nifty 500market median 0.0% · five sessions −1.0% (−3.5 pts vs Nifty 500) · volume 0.5× usual · delivery −1.9 pts against usual · The announcement (opens in a new tab)
- 25 Nov 2022Board or managers changedup 1.14%+0.8 pts vs Nifty 500market median 0.0% · five sessions −0.6% (−2.6 pts vs Nifty 500) · volume 0.6× usual · delivery −13.0 pts against usual · The announcement (opens in a new tab)
- 31 May 2022Dividenddown 0.70%−0.5 pts vs Nifty 500market median 0.0% · five sessions −0.4% (+0.3 pts vs Nifty 500) · volume 1.3× usual · delivery +5.5 pts against usual · The announcement (opens in a new tab)
- 22 Feb 2022Credit ratingdown 3.60%−2.9 pts vs Nifty 500market median 0.0% · five sessions +8.4% (+10.4 pts vs Nifty 500) · volume 0.4× usual · delivery +9.6 pts against usual · The announcement (opens in a new tab)
- 22 Dec 2021Credit ratingup 2.94%+1.7 pts vs Nifty 500market median 0.0% · five sessions +4.0% (+1.2 pts vs Nifty 500) · volume 0.5× usual · delivery −7.0 pts against usual · The announcement (opens in a new tab)
- 12 Nov 2021Resultsdown 1.88%−3.0 pts vs Nifty 500market median −0.7% · five sessions −5.3% (−4.6 pts vs Nifty 500) · volume 1.2× usual · delivery +12.7 pts against usual · The announcement (opens in a new tab)
- 15 Sep 2021Credit ratingup 8.15%+7.4 pts vs Nifty 500market median 0.0% · five sessions +8.4% (+8.1 pts vs Nifty 500) · volume 6.6× usual · delivery −22.6 pts against usual · The announcement (opens in a new tab)
- 30 Jun 2021Dividendup 4.95%+5.0 pts vs Nifty 500market median 0.0% · five sessions −0.9% (−1.6 pts vs Nifty 500) · volume 2.5× usual · The announcement (opens in a new tab)
- 16 Mar 2021Credit ratingup 0.16%+0.1 pts vs Nifty 500market median 0.0% · five sessions −7.1% (−5.7 pts vs Nifty 500) · volume 4.0× usual · delivery −1.9 pts against usual · The announcement (opens in a new tab)
- 17 Aug 2020Credit ratingup 1.03%+0.5 pts vs Nifty 500market median 0.0% · five sessions −0.2% (−2.5 pts vs Nifty 500) · volume 0.4× usual · delivery +6.0 pts against usual · The announcement (opens in a new tab)
- 13 Aug 2020Credit ratingup 1.12%+0.9 pts vs Nifty 500market median 0.0% · five sessions −1.9% (−3.3 pts vs Nifty 500) · volume 1.6× usual · delivery −3.3 pts against usual · The announcement (opens in a new tab)
- 25 Feb 2020Board or managers changeddown 1.60%−1.3 pts vs Nifty 500market median 0.0% · five sessions +2.3% (+8.2 pts vs Nifty 500) · volume 0.4× usual · delivery +13.4 pts against usual · The announcement (opens in a new tab)
- 12 Feb 2020Resultsup 1.49%+1.0 pts vs Nifty 500market median −0.7% · five sessions −8.7% (−7.3 pts vs Nifty 500) · volume 0.5× usual · delivery −4.2 pts against usual · The announcement (opens in a new tab)
- 15 Nov 2019Resultsdown 3.97%−4.1 pts vs Nifty 500market median −0.7% · five sessions −10.1% (−10.8 pts vs Nifty 500) · volume 0.5× usual · delivery −1.8 pts against usual · The announcement (opens in a new tab)
- 28 Aug 2019Credit ratingup 2.90%+3.5 pts vs Nifty 500market median 0.0% · five sessions +2.1% (+4.2 pts vs Nifty 500) · volume 0.9× usual · delivery −2.8 pts against usual · The announcement (opens in a new tab)
- 1 Jul 2019Board or managers changedup 4.32%+3.7 pts vs Nifty 500market median 0.0% · five sessions +1.3% (+1.3 pts vs Nifty 500) · volume 1.2× usual · delivery −9.8 pts against usual · The announcement (opens in a new tab)
Bal Pharma results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
The latest 30. Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Provisions due within a year | At Mar 2026 | Consolidated | 0.77 | 0.77 | 0.0% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |
| Change in other current assets | Year to date to Mar 2026 | Consolidated | 16.82 | −13.66 | −181.2% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |
| Reserves | Year to Mar 2026 | Consolidated | 66.31 | 66.30 | 0.0% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |
| Total assets | At Mar 2026 | Consolidated | 375.54 | 375.54 | 0.0% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |
| Finance costs added back | Year to Mar 2026 | Consolidated | −0.85 | 16.82 | +2,086.0% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |
| Change in inventories | Year to Mar 2026 | Consolidated | −0.06 | −13.33 | −23,666.8% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |
| Reserves | Year to date to Mar 2026 | Consolidated | 66.31 | 66.30 | 0.0% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |
| Depreciation and amortisation | Quarter to Mar 2026 | Consolidated | 3.06 | 3.06 | 0.0% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |
| Other assets held for longer than a year | At Mar 2026 | Consolidated | 3.01 | 3.01 | 0.0% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |
| Liabilities due within a year | At Mar 2026 | Consolidated | 249.23 | 249.23 | 0.0% | 27 May 2026 (opens in a new tab) | 22 Jul 2026 (opens in a new tab) |